
Anne Sophie Chrétien

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9424409/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncolmmunology, 2019, 8, e1561120.	4.6	92
2	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Frontiers in Immunology, 2014, 5, 122.	4.8	75
3	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. Frontiers in Immunology, 2017, 8, 573.	4.8	47
4	Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nature Communications, 2022, 13, .	12.8	45
5	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. Oncolmmunology, 2017, 6, e1307491.	4.6	37
6	Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. Oncolmmunology, 2019, 8, 1615818.	4.6	34
7	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. Oncotarget, 2017, 8, 49548-49563.	1.8	34
8	PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncology Reports, 2009, 21, 731-5.	2.6	33
9	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	29
10	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Frontiers in Immunology, 2016, 7, 94.	4.8	26
11	Using one-step nucleic acid amplification (OSNA) for intraoperative detection of lymph node metastasis in breast cancer patients avoids second surgery and accelerates initiation of adjuvant therapy. Annals of Oncology, 2013, 24, 2305-2309.	1.2	25
12	Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. Journal of Leukocyte Biology, 2021, 109, 1071-1088.	3.3	25
13	Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia. Frontiers in Immunology, 2015, 6, 564.	4.8	24
14	JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. Cancer Research, 2017, 77, 6627-6640.	0.9	23
15	P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Therapy, 2009, 16, 498-507.	4.6	19
16	Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer. Clinical Chemistry, 2009, 55, 1327-1336.	3.2	18
17	Optimization of routine <scp><i>KRAS</i></scp> mutation <scp>PCR</scp> â€based testing procedure for rational individualized firstâ€lineâ€targeted therapy selection in metastatic colorectal cancer. Cancer Medicine, 2013, 2, 11-20.	2.8	18
18	Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line. International Journal of Oncology, 2010, 37, 1555-63.	3.3	11

#	Article	IF	CITATIONS
19	Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study. Blood, 2021, 138, 1817-1817.	1.4	5
20	Human plasmacytoid dendritic cells regulate IFN-α production through activation-induced splicing of IL-18Rα. Journal of Leukocyte Biology, 2014, 96, 1037-1046.	3.3	4
21	Anti-BTN3A 20.1 Agonist Monoclonal Antibody Enhances Autologous Vγ9Vδ2 T Cells Cytotoxicity Against Primary Acute Myeloid Blasts. Blood, 2019, 134, 5153-5153.	1.4	4